Stock listing
NASDAQ:LONA LeonaBio, Inc. Stock
Home listing (NASDAQ) of LeonaBio, Inc.
Follow LeonaBio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LONA
$2.02 USD -0.44 (-17.9%)
Close on Nov 20, 2026
- Day range
- $1.91 – $2.49 USDNov 20, 2026
- Volume
- 68,874 sharesNov 20, 2026
- Market cap
- $19.03M USDAt the close on Nov 20, 2026 · price × 9.42M shares outstanding
- 52-week range
- $1.91 – $14.21 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $874,601 USDMedian day 47,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LONA · Home | $2.02 USD | -0.44 (-17.9%) | 68,874 | $2.36 | $2.485 | $1.91 | $2.46 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LONA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.02 | -0.44 | -17.9% | $2.36 | $2.485 | $1.91 | 68,874 | |
| $2.46 | -0.19 | -7.2% | $2.71 | $2.93 | $2.37 | 84,853 | |
| $2.65 | -0.11 | -4.0% | $2.77 | $3.052 | $2.51 | 44,498 | |
| $2.76 | -0.47 | -14.6% | $3.17 | $3.32 | $2.75 | 24,683 | |
| $3.23 | -0.24 | -6.9% | $3.47 | $3.47 | $3.20 | 58,410 | |
| $3.47 | -0.26 | -7.0% | $3.75 | $3.95 | $3.46 | 20,000 | |
| $3.73 | -0.15 | -3.9% | $3.898 | $3.92 | $3.623 | 25,500 | |
| $3.88 | -0.14 | -3.5% | $4.055 | $4.055 | $3.60 | 33,000 | |
| $4.02 | -0.45 | -10.1% | $4.47 | $4.75 | $4.01 | 86,100 | |
| $4.47 | +0.055 | +1.2% | $4.44 | $4.80 | $4.25 | 99,200 | |
| $4.415 | +0.075 | +1.7% | $4.20 | $4.673 | $4.13 | 50,000 | |
| $4.34 | -0.225 | -4.9% | $4.55 | $4.83 | $4.26 | 94,500 | |
| $4.565 | -0.205 | -4.3% | $4.80 | $4.90 | $4.53 | 74,300 | |
| $4.77 | +0.04 | +0.8% | $4.69 | $4.90 | $4.69 | 28,500 | |
| $4.73 | -0.21 | -4.3% | $4.95 | $5.03 | $4.63 | 26,700 | |
| $4.94 | +0.03 | +0.6% | $4.89 | $5.14 | $4.76 | 43,100 | |
| $4.91 | -0.05 | -1.0% | $5.20 | $5.40 | $4.74 | 161,800 | |
| $4.96 | +0.07 | +1.4% | $4.94 | $5.10 | $4.76 | 124,800 | |
| $4.89 | +0.13 | +2.7% | $4.77 | $5.10 | $4.68 | 118,700 | |
| $4.76 | -0.08 | -1.7% | $4.80 | $5.00 | $4.55 | 38,900 | |
| $4.84 | -0.13 | -2.6% | $4.99 | $5.02 | $4.83 | 33,800 | |
| $4.97 | -0.70 | -12.3% | $5.59 | $5.671 | $4.69 | 49,800 | |
| $5.67 | +0.40 | +7.6% | $5.30 | $5.75 | $5.30 | 11,800 | |
| $5.27 | +0.22 | +4.4% | $5.11 | $5.46 | $4.86 | 61,500 | |
| $5.05 | -0.15 | -2.9% | $5.23 | $5.385 | $4.77 | 41,000 | |
| $5.20 | -0.09 | -1.7% | $5.30 | $5.43 | $5.15 | 61,300 | |
| $5.29 | -0.10 | -1.9% | $5.41 | $5.44 | $4.91 | 35,200 | |
| $5.39 | -1.04 | -16.2% | $6.33 | $6.33 | $5.25 | 103,000 | |
| $6.43 | +0.265 | +4.3% | $6.06 | $6.72 | $5.649 | 57,400 | |
| $6.165 | +0.415 | +7.2% | $5.82 | $6.397 | $5.57 | 386,300 | |
| $5.75 | 0.00 | 0.0% | $5.82 | $6.10 | $5.56 | 66,700 | |
| $5.75 | -0.08 | -1.4% | $5.78 | $6.07 | $5.515 | 134,600 | |
| $5.83 | +0.08 | +1.4% | $5.77 | $6.21 | $5.61 | 178,100 | |
| $5.75 | +0.17 | +3.0% | $5.63 | $5.88 | $5.25 | 175,600 | |
| $5.58 | +0.76 | +15.8% | $4.75 | $5.72 | $4.51 | 295,600 | |
| $4.82 | +0.44 | +10.0% | $4.44 | $4.90 | $4.18 | 332,100 | |
| $4.38 | +0.81 | +22.7% | $3.515 | $5.34 | $3.42 | 6,300,400 | |
| $3.57 | +0.06 | +1.7% | $3.51 | $3.59 | $3.31 | 40,300 | |
| $3.51 | +0.64 | +22.3% | $2.80 | $3.75 | $2.57 | 439,100 | |
| $2.87 | -0.38 | -11.7% | $3.30 | $3.30 | $2.21 | 948,900 | |
| $3.25 | -1.74 | -34.9% | $5.19 | $5.595 | $3.12 | 343,700 | |
| $4.99 | -0.90 | -15.3% | $6.04 | $6.315 | $4.90 | 151,000 | |
| $5.89 | -0.16 | -2.6% | $6.35 | $6.35 | $5.69 | 21,400 | |
| $6.05 | -0.28 | -4.4% | $6.40 | $6.75 | $5.95 | 34,900 | |
| $6.33 | -0.46 | -6.8% | $6.715 | $6.76 | $6.23 | 45,600 | |
| $6.79 | -0.16 | -2.3% | $7.59 | $7.655 | $6.61 | 52,300 | |
| $6.95 | +0.16 | +2.4% | $6.86 | $6.95 | $6.725 | 5,500 | |
| $6.79 | -0.45 | -6.2% | $7.10 | $7.30 | $6.696 | 51,300 | |
| $7.24 | -0.23 | -3.1% | $6.90 | $7.47 | $6.90 | 23,400 | |
| $7.47 | +0.55 | +7.9% | $7.02 | $7.80 | $7.02 | 23,300 | |
| $6.92 | +0.06 | +0.9% | $6.75 | $7.64 | $6.75 | 42,700 | |
| $6.86 | -0.18 | -2.6% | $7.14 | $7.705 | $6.81 | 42,300 | |
| $7.04 | -0.98 | -12.2% | $7.90 | $8.195 | $7.04 | 78,900 | |
| $8.02 | +0.46 | +6.1% | $7.56 | $8.27 | $7.43 | 259,300 | |
| $7.56 | -0.14 | -1.8% | $7.925 | $7.925 | $7.439 | 14,200 | |
| $7.70 | +0.03 | +0.4% | $7.59 | $8.07 | $7.54 | 7,600 | |
| $7.67 | +0.08 | +1.1% | $7.72 | $7.805 | $7.67 | 5,700 | |
| $7.59 | -0.33 | -4.2% | $7.89 | $8.345 | $7.59 | 154,400 | |
| $7.92 | -0.02 | -0.3% | $8.025 | $8.40 | $7.92 | 34,200 | |
| $7.94 | +0.05 | +0.6% | $8.00 | $8.00 | $7.94 | 5,100 | |
| $7.89 | +0.08 | +1.0% | $8.155 | $8.16 | $7.89 | 3,500 | |
| $7.81 | -0.20 | -2.5% | $8.05 | $8.125 | $7.76 | 24,400 | |
| $8.01 | +0.28 | +3.6% | $7.76 | $8.21 | $7.705 | 11,700 | |
| $7.73 | +0.045 | +0.6% | $7.57 | $8.115 | $7.55 | 8,400 | |
| $7.685 | -0.015 | -0.2% | $7.88 | $7.99 | $7.60 | 9,600 | |
| $7.70 | -0.13 | -1.7% | $7.95 | $8.11 | $7.57 | 9,000 |
Splits
1 split · NASDAQ:LONA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:LONA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 36 slides
Latest news
LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 16, 2026
Closed $2.76 (-14.6%) on Nov 17, 2026
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
Sep 3, 2026
Closed $7.70 (+0.4%) on Sep 3, 2026
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
Aug 12, 2026
Closed $7.87 (+3.3%) on Aug 12, 2026
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
Jun 4, 2026
Closed $8.61 (-0.2%) on Jun 4, 2026
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
May 27, 2026
Closed $9.81 (+1.4%) on May 27, 2026
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
May 7, 2026
Closed $9.86 (+4.7%) on May 7, 2026
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
Apr 23, 2026
Closed $8.33 (-3.4%) on Apr 24, 2026
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
Apr 21, 2026
Closed $9.22 (-1.7%) on Apr 21, 2026
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Mar 26, 2026
Closed $9.68 (+7.2%) on Mar 26, 2026
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Feb 3, 2026
Closed $4.65 (0.0%) on Feb 3, 2026
LeonaBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 11 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 10 decks · latest August 2026
Where LeonaBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LONA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LONA | BOATS | United States | USD |
| Frankfurt:6AI | Frankfurt | Germany | EUR |
Valuation
Price/book 1.2× against a median of 1.7×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$12.82M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.04
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Aardvark Therapeutics, Inc. · NASDAQ:AARD | US$20.20M | −US$39.58M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 3.28 |
| GenSight Biologics SA · EURONEXT:SIGHT | US$20.19M | US$32.44M | n/a | 29,573× | n/a | n/a | n/a | n/a | n/a |
| TransCode Therapeutics, Inc. · NASDAQ:RNAZ | US$20.07M | US$15.44M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 1.03 |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| Cocrystal Pharma, Inc. · NASDAQ:COCP | US$18.30M | US$14.69M | n/a | 33.8× | n/a | 6.8× | n/a | 0.5× | 1.21 |
| Syntara Limited · ASX:SNT | US$18.20M | US$9.23M | n/a | 2.0× | n/a | 1.7× | −129.8% | 0.0× | n/a |
| Marker Therapeutics, Inc. · NASDAQ:MRKR | US$18.17M | US$9.13M | n/a | 4.9× | n/a | 1.7× | −461.1% | 0.0× | 1.49 |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| Median of the others | US$19.36M | US$15.06M | 19.3× | 1.7× | −295.4% | 0.0× | 1.15 |
Forecasts
2 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.88 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mark Litton | President & CEO |
| Natalie Holles | Board Member | Chief Executive Officer |
| Robert Renninger | Chief Financial Officer |
| Mark Worthington | General Counsel, Chief Compliance Officer, & Corporate Secretary |
| Javier San Martin | Chief Medical Officer |
| Kevin Church | Chief Scientific Officer |
| Mark F. Kubik | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Kelly Romano | Chair |
| Barbara Kosacz | Board Member |
| Fred Callori | Board Member |
| Grant Pickering | Board Member |
| James Johnson | Board Member |
| Joe Edelman | Board Member |
| Mark Litton | President & CEO |
| Michael A. Panzara | Board Member |
| Natalie Holles | Board Member | Chief Executive Officer |
| Peter B. Silverman | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −14.6% |
| Q2 2026 | Aug 14, 2026 · After close | −3.2% |
| Q1 2026 | May 7, 2026 · After close | +1.8% |
| Q4 2025 | Mar 27, 2026 | −4.3% |
| Q3 2025 | Nov 6, 2025 · After close | −4.0% |
| Q2 2025 | Aug 7, 2025 · After close | +6.0% |
| Q1 2025 | May 9, 2025 · After close | +6.3% |
| Q4 2024 | Feb 27, 2025 | −6.4% |
| Q3 2024 | Nov 7, 2024 · After close | −12.0% |
| Q2 2024 | Aug 1, 2024 · After close | −1.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +22.6% |
| Q4 2023 | Feb 22, 2024 · After close | 0.0% |
| Q3 2023 | Nov 9, 2023 · After close | +6.5% |
| Q2 2023 | Aug 10, 2023 · After close | −7.3% |
| Q1 2023 | May 11, 2023 · After close | 0.0% |
| Q4 2022 | Mar 23, 2023 | −1.6% |
| Q3 2022 | Nov 10, 2022 · After close | +8.4% |
| Q2 2022 | Aug 15, 2022 · After close | +1.5% |
| Q1 2022 | May 12, 2022 · After close | +4.0% |
| Q4 2021 | Mar 24, 2022 | +13.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 36 slides | August 2026 |
| Investor Presentation (March 2026) | Investor deck | 41 slides | Mar 26, 2026 |
| Athira Pharma — Investor Presentation (December 2025) | Investor deck | 42 slides | Dec 18, 2025 |
| Athira Pharma — Technical Presentation (September 2024) | Technical | 15 slides | Sep 3, 2024 |
| Athira Pharma — Corporate Update (October 2022) | Corporate update | 11 slides | Oct 17, 2022 |
| Athira Pharma — Technical Presentation (June 2022) | Technical | 17 slides | Jun 22, 2022 |
| Athira Pharma — Proxy Contest (April 2022) | Proxy contest | 36 slides | Apr 26, 2022 |
| Athira Pharma — Proxy Contest (April 2022) | Proxy contest | 53 slides | Apr 25, 2022 |
| Athira Pharma — Investor Presentation (April 2022) | Investor deck | 32 slides | Apr 11, 2022 |
| Athira Pharma — Investor Presentation (January 2021) | Investor deck | 31 slides | Jan 11, 2021 |
IPO
Went public as Athira Pharma, Inc. Priced at US$17.00 a share on Sep 17, 2020.
- Price
- US$17.00 a share
- Shares offered
- 12,000,000 shares of common stock
- Offering size
- US$204 million
- Underwriters' option
- Up to 1,800,000 more shares
- Listing
- ATHA on the Nasdaq Global Select Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Stifel, JMP Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 24, 2020 |
| Filed publicly | Aug 26, 2020 |
| Amended 3 times | Newest Sep 17, 2020 |
| Shares registered with an exchange | Sep 9, 2020 |
| Declared effective by the SEC | Sep 17, 2020 |
| Final prospectus, with the price | Sep 18, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 18, 2020 |
| EFFECT · Notice that a registration is effective | Sep 17, 2020 |
| S-1MEF · Registration of more shares for the same offering | Sep 17, 2020 |
| CORRESP · Letter to the SEC | Sep 17, 2020 |
| S-1/A · Registration statement, amended | Sep 17, 2020 |
| UPLOAD · Letter from the SEC | Sep 16, 2020 |
| CERT · Exchange's certificate of listing | Sep 16, 2020 |
| CORRESP · Letter to the SEC | Sep 14, 2020 |
| CORRESP · Letter to the SEC | Sep 14, 2020 |
| S-1/A · Registration statement, amended | Sep 14, 2020 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 14, 2020 |
| UPLOAD · Letter from the SEC | Sep 10, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 9, 2020 |
| S-1/A · Registration statement, amended | Sep 9, 2020 |
| CORRESP · Letter to the SEC | Sep 2, 2020 |
| CORRESP · Letter to the SEC | Aug 26, 2020 |
| S-1 · Registration statement | Aug 26, 2020 |
| UPLOAD · Letter from the SEC | Aug 21, 2020 |
| DRS · Draft registration statement | Jul 24, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jul 24, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 68.1M | 479.0K | 2.00M | |||||
| Gross profit | -68.1M | -479.0K | -2.00M | |||||
| Research and development | 17.5M | 70.7M | 93.8M | 61.5M | 42.8M | 13.3M | 3.79M | 3.59M |
| Selling, general and administrative | 16.7M | 26.1M | 33.3M | 32.6M | 21.2M | 6.71M | 1.66M | 1.42M |
| Operating income | -102.3M | -100.9M | -125.5M | -104.0M | -64.0M | -20.0M | -5.45M | -5.01M |
| Depreciation and amortization | 972.0K | 970.0K | 969.0K | 845.0K | 479.0K | 2.00K | 2.00K | 5.01M |
| EBITDA | -101.3M | -99.9M | -124.5M | -103.2M | -63.5M | -20.0M | -5.45M | 0 |
| Interest expense | 24.3M | 3.00K | 367.0K | 346.0K | 9.00K | |||
| Income before tax | -105.6M | -96.9M | -117.4M | -95.8M | -55.0M | -20.0M | -5.16M | -5.10M |
| Income tax | 0 | |||||||
| Net income | -105.6M | -96.9M | -117.7M | -95.6M | -54.9M | -20.0M | -5.16M | -5.10M |
| Earnings per share, basic | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | -1.67 | -1.45 | -1.56 |
| Earnings per share, diluted | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | -1.67 | -1.45 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 69.3M | 48.4M | 90.6M | 96.0M | 110.5M | 60.6M | 2.06M | 3.32M |
| Short-term investments | 19.1M | 2.84M | 56.8M | 104.4M | 143.2M | 124.1M | 1.50M | |
| Receivables | 1.63M | 1.23M | 2.34M | 1.30M | 7.00K | 6.00K | ||
| Inventory | -1.23M | |||||||
| Current assets | 89.5M | 54.8M | 154.7M | 207.5M | 260.8M | 192.3M | 2.16M | 4.90M |
| Property, plant and equipment | 1.47M | 2.44M | 3.39M | 4.05M | 3.76M | 2.65M | ||
| Total assets | 92.2M | 58.8M | 160.2M | 258.2M | 332.0M | 279.6M | 2.19M | 4.93M |
| Accounts payable | 4.59M | 319.0K | 129.0K | 2.50M | 567.0K | 1.16M | 421.0K | 121.0K |
| Current liabilities | 47.5M | 13.1M | 28.8M | 21.4M | 9.29M | 4.41M | 1.27M | 572.0K |
| Total debt | 803.0K | 1.22M | 1.58M | 1.91M | 1.92M | 1.00M | 1.55M | 722.0K |
| Total liabilities | 64.4M | 13.9M | 30.1M | 23.0M | 10.9M | 5.28M | 4.86M | 19.8M |
| Shareholders' equity | 27.8M | 44.8M | 130.2M | 235.1M | 321.1M | 274.3M | -19.7M | -14.9M |
| Shares outstanding | 9.34M | 3.90M | 38.2M | 37.9M | 37.4M | 32.5M | 3.64M | 3.26M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -45.7M | -97.2M | -100.8M | -72.5M | -43.1M | -24.1M | -3.71M | -4.48M |
| Capital spending | 0 | -33.0K | -304.0K | -1.14M | -1.57M | -2.32M | 0 | 0 |
| Free cash flow | -45.7M | -97.2M | -101.1M | -73.6M | -44.7M | -26.4M | -3.71M | -4.48M |
| Cash from investing | -15.9M | 54.8M | 95.1M | 57.7M | -4.08M | -210.1M | 1.51M | 2.01M |
| Cash from financing | 82.5M | 194.0K | 493.0K | 654.0K | 97.1M | 292.8M | 946.0K | 1.46M |
| Change in cash | 20.8M | -42.1M | -5.17M | -14.2M | 49.9M | 58.6M | -1.26M | -1.01M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D · Big-stake notice | Aug 31, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 26, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 25, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 20, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 11, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 11, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 11, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 31, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K/A · Current report, amended | Mar 31, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 19, 2026 | Management or board change | SEC |
| DEFR14A | Mar 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Feb 23, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Feb 20, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 11, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 11, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 4, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | Jan 20, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jan 20, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 18, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Dec 18, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 18, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 31, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Oct 29, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 24, 2024 | Other filings | SEC |
| S-3 · Registration statement | Oct 21, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 18, 2024 | Current report | SEC |
| 8-K · Current report | Oct 7, 2024 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 9, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 9, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2024 | Meeting notice | SEC |
This page holds 200 of 472 filings. Open Filings
Cap table
Built by 6ix from LeonaBio, Inc.’s releases
- Common shares
- 9,421,663
- Fully diluted
- 9,421,663
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 9,421,663 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 9,421,663 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Gengos Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past) | CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past |
| Barbara Kosacz Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2025); CERo Therapeutics Holdings, Inc. (Director · Oct 5, 2021 – Feb 14, 2024 · Past); Kronos Bio Inc (COO & General Counsel · Oct 8, 2020 – Jan 4, 2024 · Past) | Board Member · Since at least Mar 4, 2021 |
| Fred Callori Other companies: Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Landos Biopharma Inc (Director · Aug 27, 2021 – May 23, 2024 · Past) | Director · Since at least May 5, 2026 |
| John M Fluke Jr Other companies: Cellcyte Genetics Corporation (Interim PEO, Director · Jun 1, 2009 – Nov 8, 2011 · Past); PACCAR Inc. (Director · Jan 2, 2009 – Mar 5, 2015 · Past) | Director · Since at least Sep 17, 2020 |
| Mark Litton Other companies: Alpine Immune Sciences Inc (See Remarks · Aug 6, 2018 – Feb 6, 2019 · Past); Alder BioPharmaceuticals Inc (Chief Business Officer · May 7, 2014 – Jun 1, 2018 · Past) | President & CEO · Since at least Sep 17, 2020 |
| Michael A. Panzara Other companies: Immunic, Inc. (Chief Medical Officer · Since at least Apr 24, 2026); Wave Life Sciences Ltd. (See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past) | Director · Since at least Mar 18, 2022 |
| Martin Javier San Other companies: Arrowhead Pharmaceuticals, Inc. (Chief Medical Officer · Nov 21, 2022 – Jan 4, 2024 · Past) | CHIEF MEDICAL OFFICER · Since at least Apr 15, 2024 |
| Fred Callori | Board Member · Since at least May 7, 2026 |
| Grant Pickering | Board Member · Since at least Nov 5, 2026 |
| James Johnson | Board Member · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Javier San Martin | Chief Medical Officer · Since at least Jun 4, 2026 |
| Joe Edelman | Board Member · Since at least Nov 4, 2026 |
| Kelly Romano | Chair · Since at least Nov 5, 2026 |
| Kevin Church | Chief Scientific Officer · Since at least Jun 30, 2025 |
| Leen Kawas | President & CEO, Director · Sep 17, 2020 – Feb 18, 2021 · Past |
| Mark F. Kubik | Chief Business Officer · Since at least Feb 3, 2026 |
| Mark Worthington | General Counsel, Chief Compliance Officer, & Corporate Secretary · Since at least Jun 1, 2021 |
| Natalie Holles | Board Member | Chief Executive Officer · Since at least May 7, 2026 |
| Peter B. Silverman | Board Member · Since at least May 5, 2026 |
| Rachel Lenington | COO and CDO · Jan 4, 2024 – Sep 3, 2024 · Past |
| Robert Renninger | Chief Financial Officer · Since at least Oct 1, 2024 |
Log in to ask 6ix AI your own questions about LeonaBio, Inc.